Post job

Intracel Resources main competitors are Gilead Sciences, Vertex Pharmaceuticals, and Sarepta Therapeutics.

Competitor Summary. See how Intracel Resources compares to its main competitors:

  • Merck has the most employees (74,000).
  • Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
  • The oldest company is Merck, founded in 1891.
Work at Intracel Resources?
Share your experience

Intracel Resources vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2007
3.5
Baltimore, MD1$284.9K30
1981
4.8
Cambridge, MA1$4.6B12,000
1992
4.9
Rockville, MD1$131.0M1,000
1987
4.5
Foster City, CA9$28.8B11,800
1980
4.8
Cambridge, MA2$1.9B840
1989
4.6
Boston, MA5$11.0B3,400
1992
4.8
Lexington, MA1$926.4M873
GlobeImmune
1995
3.5
Louisville, CO1$6.5M22
2002
4.8
Cambridge, MA2$2.2B1,323
1988
4.2
Gaithersburg, MD1$1.7B5,000
1979
4.7
San Diego, CA3$1.7B1,500
1891
4.6
Kenilworth, NJ31$64.2B74,000
C and O Employees' Hospital Association
1897
3.8
Clifton Forge, VA2$50.0M11
All Chicago
1973
3.5
Chicago, IL1$4.6M20

Rate how well Intracel Resources differentiates itself from its competitors.

Zippia waving zebra

Intracel Resources salaries vs competitors

Among Intracel Resources competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare Intracel Resources salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Intracel Resources
$51,529$24.77-
Sanofi Genzyme
$84,495$40.62-
Human Genome Sciences
$70,157$33.73-
Gilead Sciences
$99,828$47.99-
Sarepta Therapeutics
$94,985$45.67-
Vertex Pharmaceuticals
$95,952$46.13-

Compare Intracel Resources job title salaries vs competitors

CompanyHighest salaryHourly salary
Intracel Resources
$37,856$18.20
Gilead Sciences
$41,880$20.13
Merck
$40,936$19.68
Vertex Pharmaceuticals
$39,645$19.06
GlobeImmune
$38,923$18.71
Quidel
$38,009$18.27
Sanofi Genzyme
$36,710$17.65
Sarepta Therapeutics
$36,103$17.36
Cubist Pharmaceuticals
$35,522$17.08
Human Genome Sciences
$35,014$16.83
Med Immune Inc
$33,730$16.22
Alnylam Pharmaceuticals
$32,984$15.86
C and O Employees' Hospital Association
$32,235$15.50
All Chicago
$32,196$15.48

Do you work at Intracel Resources?

Does Intracel Resources effectively differentiate itself from competitors?

Intracel Resources jobs

Intracel Resources demographics vs competitors

Compare gender at Intracel Resources vs competitors

Job titleMaleFemale
Sarepta Therapeutics44%56%
Alnylam Pharmaceuticals49%51%
Merck54%46%
Gilead Sciences56%44%
Quidel58%42%
Intracel Resources--
Male
Female
100%
75%
50%
25%
0%
0%
25%
50%
75%
100%

Compare race at Intracel Resources vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
59%14%5%16%6%
9.1
44%20%8%23%6%
9.8
56%16%10%14%4%
9.8
50%24%8%14%5%
9.8
66%12%5%13%4%
9.3
56%14%7%17%6%
9.7

Intracel Resources and similar companies CEOs

CEOBio
Yvonne L. Greenstreet
Alnylam Pharmaceuticals

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Daniel O’Day
Gilead Sciences

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Douglas C. Bryant
Quidel

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

Douglas S. Ingram
Sarepta Therapeutics

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

Reshma Kewalramani M.d
Vertex Pharmaceuticals

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Paul Hudson
Sanofi Genzyme

Intracel Resources competitors FAQs

Search for jobs